A novel drug combination
Tiltan Pharma is an Israeli biopharmaceutical company, established in 2006, that developed a proprietary anti-angiogenic and immune modulatory platform technology...
Tiltan has developed a proprietary combinatorial drug therapy that consists of metronomic chemotherapy together with...
Tiltan Pharma started its first human trial with its investigational product (IP), phase 1/2, on November 2006 in Sheba Medical Center, Israel. The main objective...
TL-118—anti-angiogenic treatment in pancreatic cancer: a case report.
Built by Badboy.co.il
© copyright 2015 Tiltan Pharma